Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases: A pilot study

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 9, 2006, Pages 1064-1072

  Asteria, Corrado R ^a   Ficari, Ferdinado ^a   Bagnoli, Siro ^a   Milla, Monica ^a   Tonelli, Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antibody to TNF (Infliximab); Local injection; Perianal Crohn's disease

Indexed keywords

AZATHIOPRINE; CORTISONE; INFLIXIMAB; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRALESIONAL; MAGNETIC RESONANCE IMAGING; MALE; PILOT PROJECTS; RECTAL FISTULA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748675696     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600609941     Document Type: Article

References (53)

1. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. American Gastroenterological Association (AGA) technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-30.
2. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975;68:627-35.
3. Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum 1981;24:22-4.
4. Fielding JF. Perianal lesions in Crohn's disease. J R Coll Surg Edinb 1972;17:32-7.
5. Goebell H. Perianal complications in Crohn's disease. Neth J Med 1990;37:S47-51.
6. Greenstein AJ, Kark AE, Dreiling DA. Crohn's disease of the colon. I. Fistula in Crohn's disease of the colon, classification presenting features and management in 63 patients. Am J Gastroenterol 1974;62:419-29.
7. Marks CG, Ritchie JK, Lockhart-Mummery HE. Anal fistulas in Crohn's disease. Br J Surg 1981;68:525-7.
8. van Dongen LM, Lubbers EJ. Perianal fistulas in patients with Crohn's disease. Arch Surg 1986;121:1187-90.
9. Nordgren S, Fasth S, Hulten L. Anal fistulas in Crohn's disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 1992;7:214-8.
10. Braegger CP, MacDonald TT. Immune mechanism in chronic inflammatory bowel disease. Ann Allergy 1994;72:135-41.
11. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
12. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. and the Accent I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
13. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
14. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
15. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
16. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology,clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
17. Lichtiger S. Healing of perianal fistulae by local injection of antibody to TNF. Gastroenterology 2001;120Suppl:A3154.
18. Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P, et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum 2005;48:768-74.
19. Hughes LE. Clinical classification of perianal Crohn's disease. Dis Colon Rectum 1992;35:928-32.
20. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
21. Gregor JC, McDonald JWD, Klar N, Feagan BG. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3:265-76.
22. Guyatt G, Mitchell A, Irvine JE, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
23. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40.
24. Bernstein LH, Frank NS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65.
25. Brandt LJ, Bernstein LH, Boley SJ, Frank NS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;82:383-7.
26. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998;93:442-8.
27. Present DH, Lichtigher S. Efficacy of cyclosporine in treatment of Crohn's disease. Dig Dis Sci 39:374-80.
28. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380-8.
29. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
30. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995;123:132-42.
31. Korelitz B. Successful treatment of Crohn's disease with an immunosuppressive drug (6-mercaptopurine). In: Pena AS, Weterman IT, Booth CC, Strober W, editors. Recent advances in Crohn disease. The Hague: Nijoff; 1997. pp 478-85.
32. Malchow H, Steinhardt HJ, Lorenz-Meyer H, Strohm WD, Rasmussen S, Sommer H, et al. Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. Scand J Gastroenterol 1990;25:235-44.
33. Bell SJ, Williams AB, Wiesel Pilkinson K, Cohen RCG, Kamm MA. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:1145-51.
34. Lapidus A, Bernell O, Hellers G, Löfberg R. Clinical course of colorectal Crohn's disease: a 35 year follow-up study of 507 patients. Gastroenterology 1998;114:1151-60.
35. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32.
36. Makowiec F, Jahle EC, Starlinger M. Clinical course of perianal fistulas in Crohn's disease. Gut 1995;37:696-701.
37. Noyer CM, Brandt LJ. Hyperbaric oxygen therapy for perineal Crohn's disease. Am J Gastroenterol 1999;94:318-21.
38. Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn's disease. J Clin Gastroenterol 1994;19:202-5.
39. Vitton V, Gasmi M, Barthet M, Dejeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn's anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005;21:1453-7.
40. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-9.
41. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:543-53.
42. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-11.
43. Remicade® (Infliximab). Summary of product characteristics. The Netherlands: Centocor, B.V. Leiden; June 2005.
44. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
45. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-104.
46. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
47. Fiocchi C. Closing fistulas in Crohn's disease: should the accent be on maintenance or safety? N Engl J Med 2004;350:934-6.
48. Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol 2004;99:445-9.
49. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn's disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002;137:774-7.
50. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.
51. Poritz LS, Rowe WA, Koltun WA. Remicade® does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002;45:771-5.
52. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-93.
53. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol 2004;99:82-8.